Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Hypertension IV: Drug Therapy and Lifestyle Modifications

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Encoding of modality-specific face engrams promotes distinct recruitment of mnemonic processing mechanisms: A mobile-EEG study comparing encoding and retrieval of 2D and 3D avatars under virtual reality conditions.

NeuroImage·2026

Same author

One-Year Progression of Capillary Nonperfusion in Nonproliferative Diabetic Retinopathy Using Noninvasive Imaging: The CHART Study.

Translational vision science & technology·2026

Same author

Report of the 2023 Mary Tyler Moore Vision Initiative Workshop.

Translational vision science & technology·2025

Same author

Neuroprotective Effect of a Novel Soluble Guanylate Cyclase Activator Runcaciguat in Diabetic and Ischemic Retinopathy.

Diabetes..·2025

Same author

Identification of functional dynamic brain states based on graph attention networks.

NeuroImage·2025

Same author

Brain Evoked Response Qualification Using Multi-Set Consensus Clustering: Toward Single-Trial EEG Analysis.

Brain topography·2024

Search research articles

Related Experiment Video

Updated: May 23, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double-blind,

Rainer Düsing¹, Patrick Brunel, InYoung Baek

¹Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik, Bonn, Germany. duesing@uni-bonn.de

Journal of Hypertension

|March 24, 2012

Summary

This summary is machine-generated.

Aliskiren demonstrated a more sustained blood pressure (BP) lowering effect compared to telmisartan during a 7-day withdrawal period. This suggests aliskiren may offer extended BP control even with missed doses.

Related Experiment Videos

Last Updated: May 23, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Area of Science:

Cardiovascular Medicine
Pharmacology
Clinical Trials

Background:

Hypertension management requires sustained blood pressure control.
Assessing drug efficacy during treatment withdrawal is crucial for understanding long-term effects.

Purpose of the Study:

To evaluate the sustained blood pressure (BP)-lowering effect of aliskiren versus telmisartan after a 7-day treatment withdrawal in hypertensive patients.

Main Methods:

Randomized trial comparing once-daily aliskiren (150 mg) and telmisartan (40 mg).
Patients received a 2-week dose escalation followed by 10 weeks of active treatment.
A 7-day placebo period simulated treatment withdrawal to assess sustained BP effects.

Main Results:

Both aliskiren and telmisartan showed similar BP reductions at the end of active treatment.
During the 7-day withdrawal, aliskiren exhibited a significantly smaller increase in 24-h mean ambulatory systolic BP (2.7 mmHg vs. 6.5 mmHg) and diastolic BP (-2.1 mmHg) compared to telmisartan.
These differences favored aliskiren, with significant P-values (<0.0001) observed for both systolic and diastolic BP changes.

Conclusions:

Aliskiren provides a greater and more sustained blood pressure-lowering effect than telmisartan during a 7-day treatment withdrawal.
Aliskiren may offer sustained BP control during periods of missed medication, such as one or more missed doses.